RxDoctor Payments DataLook up a doctor →

Tu Bui, MD

Family Medicine · Hagerstown, MDNPI 1396894903

Payments from drug & device makers

$18,729in general payments, 2019–2025

Across 854 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$5K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Novo Nordisk$806
  • GSK$693
  • plus $8K from 41 others

What the payments were for

  • Consulting fees$4,91026%
  • Speaking & faculty fees$200%
  • Travel & lodging$7664%
  • Food & beverage$12,88769%
  • Education$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,729 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$38,241
Medicare patients
154
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Soliqua 100-33Insulin Glargine/Lixisenatide38$33,654
MounjaroTirzepatide18$33,154
EliquisApixaban21$29,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$20,065
JardianceEmpagliflozin17$19,995
XareltoRivaroxaban20$18,311
Janumet XrSitagliptin Phos/Metformin Hcl12$17,686
JanuviaSitagliptin Phosphate11$12,795
Atorvastatin Calcium142$1,916
Albuterol Sulfate HfaAlbuterol Sulfate28$1,527
Rosuvastatin Calcium92$1,352
Ezetimibe29$1,046
Tamsulosin Hcl38$935
Metoprolol Succinate65$889
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCSoliqua 100-33$410$33,65438 claims
Lilly USA, LLCMounjaro$1,399$33,15418 claims
MerckJanumet Xr, Januvia$88$30,48123 claims
PfizerEliquis$652$29,58121 claims
GSKTrelegy Ellipta$693$20,06516 claims
Boehringer IngelheimJardiance$656$19,99517 claims
Johnson & JohnsonXarelto$342$18,31120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →